Skip to main content
. 2020 Apr 14;16:269–280. doi: 10.2147/TCRM.S235235

Table 4.

Overview of Adverse Events (AEs) Divided into Mild, Moderate and Severe Depending on the Number of Patients, Mean Age and Contrast Agent Consumption of the Respective Studies

Patients Mild AE Moderate AE Severe AE Mean Volume/Patient Mean Number of Consultations Mean Volume/Consultations Total in mL
Muscular 425 1 0 0 10.8 1.7 6.7 4600.8
 SSP prospective 84 0 0 0 20.2 2.1 9.7 1699.2
 SSP retrospective 85 0 0 0 9.6 1.0 9.6 816.0
 RSA prospective 66 1 0 0 10.7 2.2 4.9 703.2
 RSA retrospective 64 0 0 0 4.8 1.0 4.8 307.2
 RSA in trauma 30 0 0 0 7.7 1.6 5.3 244.8
 PHILOS 43 0 0 0 5.0 1.0 5.0 216.0
 Device comparison 23 0 0 0 21.3 4.4 4.8 489.6
 Tendon regeneration 22 0 0 0 4.4 1.8 2.4 96.0
 Others 8 0 0 0 3.6 1.0 3.6 28.8
Skeletal 339 1 0 1 6.2 2.4 2.6 2116.8
 Non-unions 222 0 0 0 6.2 2.6 2.6 1387.2
 HTOWO 37 1 0 0 7.5 2.7 2.6 276.0
 Fractures 76 0 0 1 5.8 2.4 2.4 441.6
 Others 4 0 0 0 3.0 1.0 3.0 12.0
All 764 2 0 1 8.8 2.0 4.8 6717.6

Abbreviations: SSP, supraspinatus muscle; RSA, reverse shoulder arthroplasty; PHILOS, proximal humeral internal locking system (DePuy Synthes®); HTOWO, high tibial open wedge osteotomy.